Publication

Novel molecular targets in hepatic stellate cells for the treatment of liver fibrosis

Smith Cortínez, N., 2020, [Groningen]: University of Groningen. 170 p.

Research output: ThesisThesis fully internal (DIV)Academic

Copy link to clipboard

Documents

  • Title and contents

    Final publisher's version, 410 KB, PDF document

  • Chapter 1

    Final publisher's version, 1 MB, PDF document

  • Chapter 2

    Final publisher's version, 1 MB, PDF document

    Embargo ends: 07/07/2021

    Request copy

  • Chapter 3

    Final publisher's version, 2 MB, PDF document

    Embargo ends: 07/07/2021

    Request copy

  • Chapter 4

    Final publisher's version, 3 MB, PDF document

    Embargo ends: 07/07/2021

    Request copy

  • Chapter 5

    Final publisher's version, 2 MB, PDF document

    Embargo ends: 07/07/2021

    Request copy

  • Chapter 6

    Final publisher's version, 855 KB, PDF document

  • Chapter 7

    Final publisher's version, 1 MB, PDF document

  • Chapter 8

    Final publisher's version, 358 KB, PDF document

  • Complete thesis

    Final publisher's version, 12 MB, PDF document

    Embargo ends: 07/07/2021

    Request copy

  • Chapter 3 supplementary video

    Final publisher's version, 39 MB, application/octet-stream

  • Propositions

    Final publisher's version, 92 KB, PDF document

DOI

Liver fibrosis is the result of chronic liver diseases that lead to cell death and scarring due to extracellular matrix (ECM) deposition. Hepatic stellate cells (HSC) are myofibroblast-like cells that activate upon injury and produce ECM. HSC activation, from quiescent HSC (qHSC) to activated HSC (aHSC) is controlled by the pro-fibrogenic cytokine transforming growth factor-beta (TGFβ) and regulates the production of alpha-smooth muscle actin (αSMA) and collagen-I, key markers of aHSC. aHSC contribute to the progression of liver fibrosis, so finding novel drugs that prevent or reverse the activation of HSC is an important step in developing effective treatments for liver fibrosis. We investigated the contribution of mitochondrial metabolism towards HSC activation and in Chapter 2 and Chapter 3, we targeted metabolic pathways that are involved in HSC activation. Excessive ECM deposition is the process that ultimately causes the scarring of the liver causing cirrhosis. Thus, we studied the molecular mechanisms driving collagen-I export in Chapter 4 and Chapter 5, targeted key proteins in this pathway to find novel targets to treat liver fibrosis.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Supervisors/Advisors
Award date7-Jul-2020
Place of Publication[Groningen]
Publisher
Print ISBNs978-94-6375-964-9
Electronic ISBNs978-94-6375-968-7
Publication statusPublished - 2020

Download statistics

No data available

ID: 128130988